€1.9 million for mRNA technology RIBOPRO

By Team IO

RIBOPRO is focusing on biotech and biopharma through the co-creation of innovative mRNA drugs based on patented mRNA technologies. The start-up secured a €1.9 million convertible loan last week.

The convertible loan comes from existing investors Vlasroot, BOM, the Fredriks family and commissioner Wietse Mulder, who represents EchiumBio Holding BV. RIBOPRO aims to revolutionize healthcare through mRNA innovations. The funding obtained through this agreement is intended for further research into defined valorization points and streamlining production processes.

Flying start for RiboPro with production of mRNA

Scientists and biotech companies are lining up for the messenger RNA (mRNA) products that the Dutch start-up RiboPro makes. The company is therefore growing rapidly. … Continued

Sander van Asbeck, CEO of RIBOPRO expects this capital injection to provide a proof of concept for next-generation LNP technology and development. The construction of an mRNA/LNP production machine should make the company the go-to supplier of mRNA technologies and high-performance (GMP) manufacturing. “The anticipated breakthrough in the performance of our mRNA/LNP will benefit the hundreds of existing customers and accelerate the acquisition of new partnerships. We are grateful for the trust and support of our investors, which will allow us to further grow into a mature and profitable company and fulfill our mission.”